Tolterodine Tartrate ER 24HR Capsules

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D223R0001

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Ambernath, Mahārāshtra, INDIA

SourceSAM
The Defense Logistics Agency (DLA) Troop Support, a federal office under the Department of Defense, has issued an award notice for the procurement of Tolterodine Tartrate ER 24HR Capsules. This notice, identified by procurement number SPE2D223R0001, announces a contract modification (SPE2D2-23-D-0010 P00007) that exercises the third-year option of an ongoing supply agreement. The contract remains active as of July 21, 2026. The scope of this procurement centers on the manufacturing and supply of Tolterodine Tartrate Extended Release (ER) 24-hour capsules, a pharmaceutical product classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and product service code 6505 (Drugs and Biologicals). The place of performance is specified as Ambernath, Mahārāshtra, India, indicating that production or fulfillment activities are based in this location. The intended outcome of this contract modification is to ensure continued, reliable supply of Tolterodine Tartrate ER capsules to meet the needs of DLA Troop Support and its stakeholders. By exercising the third-year option, the agency demonstrates its ongoing commitment to maintaining a stable supply chain for this critical pharmaceutical product. Key requirements and expected deliverables include adherence to pharmaceutical manufacturing standards as defined by the NAICS classification, consistent quality and timely delivery of Tolterodine Tartrate ER 24HR capsules, and compliance with all applicable federal regulations governing drug procurement. Contractors are expected to maintain robust production capabilities and quality assurance processes throughout the contract lifecycle. The contracting entity, DLA Troop Support, is responsible for oversight and administration of this procurement. Primary and secondary points of contact for this opportunity are Courtney Hunter ([email protected], 4457373585) and Jason Wray ([email protected], 4457376304), respectively. Interested parties can access further details and attachments via the official SAM.gov opportunity page (https://sam.gov/opp/735d14f369fa4505acdf5d85a8724206/view). This procurement is an award notice for a contract modification, not a new solicitation, and therefore does not specify set-aside requirements or special considerations for new bidders. The contract’s core elements—pharmaceutical manufacturing, quality assurance, and supply continuity—will remain constant throughout its duration. Contractors evaluating this opportunity should note the focus on pharmaceutical manufacturing expertise, international production capabilities (specifically in India), and compliance with Department of Defense procurement standards. The contract modification reflects a stable, ongoing relationship with the supplier, emphasizing the importance of reliability and performance in fulfilling the agency’s requirements.
Documents6